Figure 1

Cytotoxicity of MOR00208 and BEN alone and in combination




Figure 2

ADCC Dose response curves




Figure 3

The amino acid sequence of the MOR00208 Variable Heavy Domain is:
(The CDRs are bolded and underlined)

EVQLVESGGGLVKPGGSLKLSCAASGYTFT**SYVMH**WVRQAPGKGLEWIGYI**NPY NDG**TKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCAR**GTYYYGTRVFDY**WG QGTLVTVSS (SEQ ID NO: 10)

The amino acid sequence of the MOR00208 Variable Light Domain is:
(The CDRs are bolded and underlined)

DIVMTQSPATLSLSPGERATLSC**RSSKSLQNVNGNTYLY**WFQQKPGQSPQLLIY**R MSNLNS**GVPDRFSGSGSGTEFTLTISSLEPEDFAVYYC**MQHLEYPIT**FGAGTKLEIK (SEQ ID NO: 11)

The amino acid sequence of the MOR00208 HCDR1 is: SYVMH (SEQ ID NO: 1)

The amino acid sequence of the MOR00208 HCDR2 is: NPYNDG (SEQ ID NO: 2)

The amino acid sequence of the MOR00208 HCDR3 is: GTYYYGTRVFDY (SEQ ID NO: 3)

The amino acid sequence of the MOR00208 LCDR1 is: RSSKSLQNVNGNTYLY (SEQ ID NO: 4)

The amino acid sequence of the MOR00208 LCDR2 is: RMSNLNS (SEQ ID NO: 5)

The amino acid sequence of the MOR00208 LCDR3 is: MQHLEYPIT (SEQ ID NO: 6)

Figure 4

Sequence of Fc regions

The amino acids sequence of the MOR00208 heavy chain Fc region is:


ASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVH
TFPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC
PAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKT
KPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQV
YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYS
KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 12)

The amino acids sequence of the MOR00208 light chain Fc region is:

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
DSKD STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 13)

Figure 5

Normalized specific killing; SD; MEC-1 target cells pretreated with Bendamustine (Ben) for 48 h before ADCC; pool of 3 independent experiments with 3 different effector cell donors



The figure shows the averages from the data shown in Table 2.

Figure 6



Percent survival
100
80
60
40
20
0
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60
Days Post-Inoculation
MOR00208 3 mg/kg
Bendamustine 13 mg/kg
Bendamustine 16 mg/kg
Bendamustine 26 mg/kg
Bendamustine/MOR00208 13/3 mg/kg
Bendamustine/MOR00208 16/3 mg/kg
Vehicle/Ref_mAb 3 mg/kg

Figure 7

	Log rank test [Comparison of Kaplan Meyer curves]	One-Way-ANOVA + Bonferroni Multiple Comparison Test
vehicle control vs MOR00208 [6 or 10 mg/kg]	ns	ns
vehicle control vs Bendamustine [13 mg/kg]	ns	ns
vehicle control vs Bendamustine [16 mg/kg]	ns	ns
vehicle control vs MOR00208/Bendamustine [10/13 mg/kg]	ns	ns
vehicle control vs MOR00208/Bendamustine [6 or 10/16 mg/kg]	* p = 0.048	ns
MOR00208 10 mg/kg vs MOR208/Bendamustine [6 or 10/16 mg/kg]	ns	ns
MOR00208 10 mg/kg vs MOR208/Bendamustine [6 or 10/13 mg/kg]	ns	ns
Bendamustine 16 mg/kg vs MOR208/Bendamustine [6 or 10/16 mg/kg]	ns	ns
Bendamustine 13 mg/kg vs MOR208/Bendamustine [6 or 10/13 mg/kg]	* p = 0.0266	ns

Figure 8

	Median days to 4000 mg	Increased time to 4000 mg [%]	Mean Tumor size at study day 34 [mg]	Reduced tumor size at study day 34 [%]
Vehicle control/Ref_mAb_33	38.1	0.00	2683	0.0
MOR00208 [6 or 10 mg/kg]	39.7	4.20	2375	11.5
Bendamustine [13 mg/kg]	38.3	0.52	2593	3.4
Bendamustine [16 mg/kg]	40.8	7.09	1948	27.4
MOR208/Bendamustine [6 or 10/13 mg/kg]	42.2	10.76	2261	15.7
MOR208/Bendamustine [6 or 10/16 mg/kg]	42.5	11.55	1771	34.0

Figure 9




5000
4000
3000
2000
1000
0
Tumor volume [mm3]
10
20
30
40
50
Days post tumor cell injection
Vehicle control/Ref_mAb_33
Bendamustine 13 mg/kg
MOR00208 6 or 10 mg/kg
MOR00208/Bendamustine 6 or 10/13

Figure 10


5000
4000
3000
2000
1000
0
Tumor volume [mm3]
10
20
30
40
50
Days post tumor cell injection
Vehicle control/Ref_mAb_33
Bendamustine 16 mg/kg
MOR00208 6 or 10 mg/kg
MOR00208/Bendamustine 6 or 10/16